Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

J Voortman

doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.5035

Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

Research output: Contribution to conference › Poster › Academic

Original language	English
DOIs	https://doi.org/10.1200/JCO.2020.38.15_suppl.5035
Publication status	Published - 2020
Event	ASCO 2020 Virtual Annual Meeting - Duration: 1 Jun 2020 → …

Conference

Conference	ASCO 2020 Virtual Annual Meeting
Period	1/06/2020 → …

Access to Document

https://doi.org/10.1200/JCO.2020.38.15_suppl.5035

Cite this

@conference{9c5cfca13efc43cebddf3043fab6bbb5,

title = "Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.",

author = "J Voortman",

year = "2020",

doi = "https://doi.org/10.1200/JCO.2020.38.15_suppl.5035",

language = "English",

note = "ASCO 2020 Virtual Annual Meeting ; Conference date: 01-06-2020",

}

TY - CONF

T1 - Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

AU - Voortman, J

PY - 2020

Y1 - 2020

U2 - https://doi.org/10.1200/JCO.2020.38.15_suppl.5035

DO - https://doi.org/10.1200/JCO.2020.38.15_suppl.5035

M3 - Poster

T2 - ASCO 2020 Virtual Annual Meeting

Y2 - 1 June 2020

ER -